Compare CCHH & HBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CCHH | HBIO |
|---|---|---|
| Founded | 2015 | 1901 |
| Country | Malaysia | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Laboratory Analytical Instruments |
| Sector | | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.6M | 26.5M |
| IPO Year | 2025 | 2000 |
| Metric | CCHH | HBIO |
|---|---|---|
| Price | $1.00 | $8.13 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 35.8K | 14.8K |
| Earning Date | 05-15-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $116,176,000.00 |
| Revenue This Year | N/A | $3.76 |
| Revenue Next Year | N/A | $5.29 |
| P/E Ratio | $43.55 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.18 | $0.38 |
| 52 Week High | $15.39 | $8.40 |
| Indicator | CCHH | HBIO |
|---|---|---|
| Relative Strength Index (RSI) | 32.27 | N/A |
| Support Level | $0.39 | N/A |
| Resistance Level | $1.02 | N/A |
| Average True Range (ATR) | 0.12 | 0.00 |
| MACD | -0.03 | 0.00 |
| Stochastic Oscillator | 0.03 | 0.00 |
CCH Holdings Ltd, through its subsidiaries, operates a specialty hotpot restaurant chain in Malaysia, specializing in chicken hotpot and fish head hotpot. The Group offers catering services in Malaysia and outside Malaysia, mainly under two brands, namely Chicken Claypot House for its chicken hotpot restaurants and Zi Wei Yuan for its fish head hotpot restaurants. It operates or licenses several restaurant outlets, among which include Chicken Claypot House, Zi Wei Yuan, 888 Family Food Courts, and other outlets under the Bibixian, Banbudian Bistro, and Chao Liu Xian Hotpot brands. A large share of its restaurants are located in Malaysia, with additional franchised outlets in Thailand, Indonesia, and China. Geographically, the Group's revenues are all derived from Malaysia.
Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, products, and services that enable advances in life science applications, including research, drug and therapy discovery, bioproduction, and preclinical testing. The company organizes its product line into two product families: Cellular and Molecular Technologies (CMT) and Preclinical. The CMT product family supports molecular, cellular, organ, and organoid research, as well as bioproduction and in vitro testing, while the Preclinical product family provides products for preclinical research and testing, including data collection and analysis for safety and regulatory compliance. Its geographical segments include the Americas, Europe, Middle East and Africa, and Asia.